Literature DB >> 12639365

Current medical, rehabilitation, and surgical management of vertebral compression fractures.

Susan S Wu1, Elisabeth Lachmann, Willibald Nagler.   

Abstract

Approximately 25% of women over the age of 50 in the United States will suffer one or more vertebral compression fractures (VCFs) related to osteoporosis. VCFs are the most common of all osteoporotic fractures, with an incidence of approximately 700,000 annually. Such a fracture may cause significant pain, disability, and loss of general health and mobility and may lead to a progressive decline in quality of life. This is a review of the clinical literature on VCFs, including patient presentation, methods of diagnosis, and current rehabilitation and medical management. Much of the pain and disability that follow a VCF may be minimized by addressing the psychological impact of such a fracture, using current medications to help limit bone loss and preserve bone mass, adhering to a well-planned rehabilitation program, and consideration of vertebroplasty or kyphoplasty in appropriate patients. A multifaceted approach will help to optimize recovery from a VCF related to osteoporosis.

Entities:  

Mesh:

Year:  2003        PMID: 12639365     DOI: 10.1089/154099903321154103

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  14 in total

1.  [Guidelines of the German Radiological Society for percutaneous vertebroplasty].

Authors:  T Helmberger; K Bohndorf; J Hierholzer; G Nöldge; D Vorwerk
Journal:  Radiologe       Date:  2003-09       Impact factor: 0.635

2.  A novel injectable porous surface modified bioactive bone cement for vertebroplasty: an in vivo biomechanical and osteogenic study in a rabbit osteoporosis model.

Authors:  Jun Chen; Jin Yu; Qiang He; Xiong Zhao; Hongxun Sang; Wei Lei; Zixiang Wu; Jingyuan Chen
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

Review 3.  Implications of analgesics use in osteoporotic-related pain treatment: focus on opioids.

Authors:  Renato Vellucci; Consalvo Mattia; Ludovica Celidonio; Rocco Domenico Mediati
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

Review 4.  Pathogenesis and clinical aspects of pain in patients with osteoporosis.

Authors:  Rocco Domenico Mediati; Renato Vellucci; Lucia Dodaro
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

Review 5.  Bone pain mechanism in osteoporosis: a narrative review.

Authors:  Consalvo Mattia; Flaminia Coluzzi; Ludovica Celidonio; Renato Vellucci
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

6.  Percutaneous vertebroplasty: the radiologist's point of view.

Authors:  Salvatore Masala; Matteo Mammucari; Francesco Paolo Maria Fucci; Francesco Massari; Giovanni Simonetti
Journal:  Clin Cases Miner Bone Metab       Date:  2010-01

7.  Balloon kyphoplasty: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2004-12-01

8.  Chronic obstructive pulmonary disease (COPD) patients with osteoporotic vertebral compression fractures (OVCFs): improvement of pulmonary function after percutaneous vertebroplasty (VTP).

Authors:  Salvatore Masala; Andrea Magrini; Amedeo Taglieri; Giovanni Nano; Antonio Chiaravalloti; Eros Calabria; Roberta Di Trapano; Antonio Pietroiusti; Giovanni Simonetti
Journal:  Eur Radiol       Date:  2014-04-18       Impact factor: 5.315

9.  Percutaneous vertebroplasty in the management of vertebral osteoporotic fractures. Short-term, mid-term and long-term follow-up of 285 patients.

Authors:  Salvatore Masala; Matteo Mammucari; Georgios Angelopoulos; Roberto Fiori; Francesco Massari; Skerdilajd Faria; Giovanni Simonetti
Journal:  Skeletal Radiol       Date:  2009-05-12       Impact factor: 2.199

10.  Cost-effectiveness of percutaneous vertebroplasty in osteoporotic vertebral fractures.

Authors:  Salvatore Masala; Anna Micaela Ciarrapico; Daniel Konda; Vincenzo Vinicola; Matteo Mammucari; Giovanni Simonetti
Journal:  Eur Spine J       Date:  2008-07-18       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.